HanchorBio Inc., a global biotechnology company dedicated to developing innovative immuno-medicines to address significant unmet medical needs in oncology and autoimmune diseases, has been awarded the 2025 Taiwan Biopharma Excellence Award at Biologics World Taiwan, hosted by IMAPAC. The company was also named “Company to Watch Out for in Taiwan”, recognizing its innovation, leadership, and growth potential in biologics development.
This industry recognition highlights HanchorBio’s significant progress in advancing its proprietary Fc-Based Designer Biologics (FBDB™) platform and underlines the company’s potential as it prepares for its next phase of corporate growth, including an anticipated IPO in Taiwan.
HanchorBio’s CEO, Dr. Scott Liu, and Senior Director of CMC (Chemistry, Manufacturing, and Controls), Dr. Vivian Kuo, were invited to the IMAPAC awards ceremony to receive this honor.
“This award is a testament to our team’s dedication to building a globally competitive biotech company in Taiwan,” said Scott Liu, Ph.D., Founder, Chairman, and CEO of HanchorBio. “We remain focused on expanding clinical development and providing better treatment options for patients worldwide while fostering talent and contributing to Taiwan’s biotech industry.”
Driving Innovation in Immunotherapy
HanchorBio’s proprietary FBDB™ platform leverages the antibody Fc region as a structural backbone to engineer next-generation multifunctional biologics with enhanced tumor specificity, improved safety, and durable efficacy. The platform integrates multi-target mechanisms to orchestrate both innate and adaptive immune responses, aiming to overcome the limitations of existing PD-1/PD-L1 checkpoint immunotherapies.
The company has successfully achieved proof-of-concept (PoC) for the FBDB™ platform in multiple tumor models, supported by strong progress in molecular design, manufacturing processes, and CMC (Chemistry, Manufacturing, and Controls) development.
Taiwan’s Emerging Global Biopharma Hub
The IMAPAC’s Taiwan Biopharma Excellence Awards recognize companies and teams driving innovation and operational excellence in biologics, cell therapies, and vaccine development. HachorBio’s award reflects its commitment to accelerating biopharma innovation and contributing to Taiwan’s growing influence in the global biotechnology ecosystem.
HanchorBio’s innovation in biologics R&D and high-quality manufacturing has earned industry-wide recognition for accelerating production timelines, reducing costs, and improving quality.
Advancing Clinical Development & Global Market Reach
HanchorBio’s lead candidate, HCB101, is currently being evaluated in multiple clinical trials across solid tumors and hematologic cancers:
• Phase 1a: Advanced solid tumors or relapsed/refractory non-Hodgkin lymphomas (NCT05892718)
• Phase 1b/2a: Evaluating efficacy and safety in advanced solid tumors
• Combination trials: HCB101 with cetuximab or bevacizumab + chemotherapy (FOLFOX or FOLFIRI) in RAS/BRAF wild-type metastatic colorectal cancer (NCT06771522)
HCB101 is a potential best-in-class Fc-fusion SIRPα variant designed to enhance immune activation with reduced hematologic toxicity. Compared to conventional CD47 monoclonal antibodies, HCB101 exhibits higher tumor-specific binding and significantly lower risk of anemia and thrombocytopenia, addressing a key limitation of existing macrophage checkpoint inhibitors.
Committed to Global Biotech Leadership
Winning the Taiwan Biopharma Excellence Award validates HanchorBio’s accomplishments and underscores its immense future potential. The recognition from IMPAC further validates HanchorBio’s innovative technology platform and its long-term strategy to become a leading global biotech company.
Dr. Scott Liu added, “We are committed to contributing to Taiwan’s biotech industry by building a globally competitive company. We aim to create an environment that attracts talent and provides more opportunities for young professionals in Taiwan.”
As global demand for cancer immunotherapies continues to rise, HanchorBio remains committed to advancing its pipeline and pursuing global partnerships to deliver accessible, next-generation immunotherapies for patients worldwide.
漢康生技 (HanchorBio Inc.) 憑藉著其創新的FBDB™技術平臺，榮獲IMAPAC舉辦的臺灣世界生物製劑會議 (Biologics World Taiwan 2025) 臺灣生物製藥卓越獎 (Taiwan Biopharma Excellence Awards) — 更被評選為「臺灣最值得關注的生技公司 (Company to Watch Out for in Taiwan)」，獲頒年度潛力獎，象徵著其在生物製劑與創新研發領域的卓越成就與未來發展潛力。
這也是漢康生技繼2024年在德國默克集團 (Merck Group) 舉辦的生物科技資助專案中獲得特等獎後，再度獲得業界認可。
漢康生技執行長劉世高及CMC(化學、製造與管制)資深總監郭孟薇受邀出席IMAPAC獲頒獎項
推動生技創新，突破免疫治療邊界
漢康生技的Fc-基因工程多功能生物藥平臺(FBDB™, Fc-Based Designer Biologics)，是用以抗體Fc區域作為骨架、開發具有特殊構型的多功能腫瘤免疫生物製劑──期以在提升安全性的同時，達到更長效、廣泛的治療效果。
透過建構具備多重靶點機制的創新生物藥，藉由先天性免疫與適應性免疫的協同調控，克服當前PD-1/PD-L1免疫療法的局限性。該技術平臺已在多種腫瘤動物模型中成功達成驗證概念(Proof-of-Concept, PoC)，展現出突破性的免疫調節潛力。通過研發創新多功能分子結構，並持續優化生產製程與CMC(化學、製造與管制)開發，漢康生技致力於開發突破性的創新療法，為尚未被滿足的臨床需求提供解決方案。
臺灣生技產業的國際影響力日益提升
本次頒獎典禮由國際知名諮詢機構 IMAPAC 主辦，旨在表彰生物製藥領域具備創新技術、卓越製造與研發突破的企業與團隊，鼓勵臺灣生技醫藥產業的發展。今年的獲獎名單涵蓋抗體、生物藥、疫苗、細胞療法等多個領域的企業，顯示出臺灣生技產業的多元發展與國際競爭力。
漢康生技在生物製劑創新研發與高品質的製造能力，在提升生產速度、降低成本與提高品質方面展現出優異的成果，因此獲得評審肯定。
未來展望：加速臨床發展，擴展全球市場
目前，漢康生技發展的藥物HCB101正在多項臨床試驗中進行評估，包括：
- 適用於晚期實體瘤或復發/難治性非霍奇金淋巴瘤(non-Hodgkin lymphomas, NHL)患者的1a期臨床試驗(NCT05892718)；
- 晚期實體瘤的療效與安全性的1b/2a期臨床試驗(NCT06771622)；
- 以及聯合西妥昔單抗(cetuximab)或貝伐珠單抗(bevacizumab)及化療(FOLFOX或FOLFIRI)在RAS/BRAF野生型(wild-type)晚期或轉移性結直腸癌(colorectal cancer, CRC)中的安全性與療效評估(HCB101-IIT-CRC-202401)。
HCB101是一款潛在全球最佳的Fc-融合SIRPα變體，專為優化免疫反應的活化，同時降低血液毒性而設計。與傳統CD47單株抗體不同，HCB101具備高專一性的腫瘤靶向結合能力，同時降低紅血球(RBC)結合，減少貧血及血小板減少等副作用，大幅地提升了安全性。
此次獲得臺灣生物製藥卓越獎，不僅是對漢康生技現有成就的肯定，更象徵著公司在未來發展道路上的巨大潛力。
漢康生技執行長劉世高表示：「希望能為臺灣做出貢獻，我們希望為臺灣打造一家能夠進軍國際的生技公司，創造一個有前景的環境廣納國際人才，更為年輕人創造更多機會。」
隨著全球對腫瘤免疫治療的需求持續攀升，漢康生技將持續以創新技術，為患者帶來更好、且能夠負擔的治療選擇。